ArticleBMC infectious diseases2025
Clinical value of metagenomic next-generation sequencing in diagnosis of Coxiella burnetii infection.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AcuteFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMetagenomic next-generation sequencing (mNGS) is a new pathogen detection technique, but the current experience of clinical application in Coxiella burnetii infection is relatively limited. This study aimed to investigate the clinical application value of mNGS in diagnosis of Coxiella burnetii infection.
methodsWe conducted a retrospective study that included patients with Coxiella burnetii infection detected by mNGS from December 2018 to August 2024. Their clinical information and mNGS test results were retrieved for analysis.
resultsA total of 70 patients with Coxiella burnetii infection were included in this study. The mean age of these patients was 43.5 years and the common clinical manifestations were fever (67/70, 95.7%), followed by headache (43/70, 61.4%), weakness (36/70, 51.4%), and muscle and joint pain (27/70, 38.6%). The mean length of hospitalization was five days. 92.9% (65/70) patients were discharged with improvement, and one patient died. The median duration of fever for these patients was seven days. Most patients temperatures returned to normal within 2-3 days after receiving targeted antibiotic therapy. No correlation was observed between the duration of fever and the reads of mNGS in febrile patients. The specimens tested by mNGS were mainly blood specimens. The reads of mNGS detected fluctuated from one to 826, with the range of one to 50 being the most frequent. 43 (61.4%) samples of mNGS detected only Coxiella burnetii. Pathogens detected along with Coxiella burnetii include viruses, bacteria, and fungi. None of the 63 patients followed up for six months had clinical manifestations of chronic Q fever.
conclusionsQ fever is a disseminated infectious disease that deserves attention for its nonspecific clinical symptoms. mNGS emerges as a powerful novel tool for pathogen detection, demonstrating significant value in diagnosing Q fever, particularly in where conventional serological and PCR testing is unavailable or inconclusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.